Rethinking Molecular Profiling after First-line Osimertinib
Abstract
A recent article presents the largest histogenomic characterization of first-line osimertinib resistance from the ORCHARD study. Dual-modality tissue and plasma sequencing detected resistance alterations in 87% of patients and polyclonal mechanisms in 46% of patients, highlighting the complexity of post-osimertinib biology and raising questions about targeted versus broadly acting regimens in the post-EGFR tyrosine kinase inhibitor setting. See related article by Yu et al., p. 3746.
Fields of Study & Subjects
Lung Cancer Treatments and Mutations
Fibroblast Growth Factor Research
Gastrointestinal Tumor Research and Treatment
Publication details
- Journal / source
- Clinical Cancer Research
- Publisher
- American Association for Cancer Research (AACR)
- Volume
- 32
- Issue
- 17
- Pages
- 3718–3720
- Publication date
- 10 July 2026
- Language
- EN